Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

Officials Downplay Debates Over Ebola Aid Response

November 21, 2014 7:58 am | by MIKE STOBBE, AP Medical Writer; MARIA CHENG, AP Medical Writer | News | Comments

U.S. officials acknowledged disagreements over coordinating the international response to the Ebola epidemic in Liberia, but they say most issues are being worked out and the overall fight against the disease there seems to be succeeding.  

TOPICS:

Ohio House Votes to Shield Execution Drugmaker

November 20, 2014 3:42 pm | by JULIE CARR SMYTH, AP Statehouse Correspondent | News | Comments

The names of companies providing lethal injection drugs to the state would be shielded for at least two decades under a bill that cleared the Ohio House on Thursday. Over objections by some Democrats that the proposal goes against government openness and risks more execution-related lawsuits, the Republican-led chamber voted 61-25 in favor of it.

TOPICS:

German Court: e-Cigarette Liquids Not Medicines

November 20, 2014 3:32 pm | News | Comments

A German federal court has ruled that the liquids contained in e-cigarettes aren't medicinal products and can be sold freely.                     

TOPICS:
Advertisement

FDA Approves Hard-to-Abuse Hydrocodone Pill

November 20, 2014 3:27 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Federal health regulators have approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards.       

TOPICS:

Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial

November 20, 2014 11:23 am | News | Comments

Anthera Pharmaceuticals has signed a manufacturing and supply agreement with the Patheon division of DPx Holdings B.V.  The contract provides for Patheon to support the production of the Sollpura clinical drug product for Anthera's Phase III registration trial.

TOPICS:

Thermoplastic Quarter Turn Electric Actuator

November 20, 2014 11:08 am | Product Releases | Comments

The ECP Series Thermoplastic Quarter Turn Electric Actuators feature a GFPP (Glass Filled Polypropylene) housing that provides the actuator superior corrosion resistance and performance in environments and atmospheres where most metal actuators cannot.

Surviving Pharma’s Uncertain Future

November 20, 2014 10:08 am | by Nathan Furr and Jeff Dyer | Articles | Comments

The average cost of developing an approved therapy is around $4.3 billion dollars for companies with three or more approved therapies, according to an analysis completed by Forbes. Imagine, then, our surprise when we discovered a biotechnology company outside of New York City that had developed three approved therapies for an average cost of $0.7 billion dollars – less than 20 percent of the industry average.

TOPICS:

Cystic Fibrosis Foundation Sells $3.3B in Vertex Drug Royalties

November 20, 2014 8:48 am | News | Comments

The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3B for innovative drugs it helped develop with Vertex Pharmaceuticals. The drug rights were acquired by Royalty Pharma, which owns royalty rights to 40 pharmaceutical medicines.

TOPICS:
Advertisement

Vetter Opens Singapore Office to Support Growing Asian Healthcare Market

November 20, 2014 8:42 am | News | Comments

Vetter has announced the opening of a new representative office in Singapore. The announcement was made at a ceremony attended by members of local government agencies and a number of executives of pharmaceutical/biotech companies with a presence in the Asian region, as well as Vetter executives.

TOPICS:

Soaring Generic Drug Prices Draw Senate Scrutiny

November 20, 2014 8:35 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.     

TOPICS:

Could Arsenic Levels in Rice Be Dangerous for Your Kids?

November 20, 2014 8:26 am | Videos | Comments

Study finds significant amount of arsenic in rice products that could have an impact on the health of people who consume it.                     

TOPICS:

McKinsey Report Says Obesity Costs Hit $2T

November 20, 2014 8:19 am | News | Comments

A new report by the McKinsey Global Institute says that the global cost of obesity has risen to $2 trillion annually — nearly as much as smoking or the combined impact of armed violence, war and terrorism.        

TOPICS:

WHO: Ebola Transmission 'Intense' in Sierra Leone

November 20, 2014 8:12 am | by CLARENCE ROY-MACAULAY, Associated Press | News | Comments

The spread of Ebola remains "intense" in most of Sierra Leone even as things have improved somewhat in the two other countries hardest hit, the World Health Organization says. Some 168 new confirmed cases emerged in a single week in Sierra Leone's capital of Freetown recently, according to a WHO report.

TOPICS:

Dupilumab Receives FDA Breakthrough Therapy Designation in Atopic Dermatitis

November 20, 2014 8:09 am | News | Comments

Regeneron Pharmaceuticals and Sanofi have announced that the FDA has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate.

TOPICS:

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals

November 20, 2014 8:00 am | News | Comments

Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading